Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00184548 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 554
- Enrollment target
NCT00184548 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 554 participants.
The verdict
NCT00184548, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 554 participants
- Enrollment target
Study Summary
This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity. Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.
Interventions
- DRUG placebo
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00184548
The ClinicalTrials.gov registry entry for NCT00184548 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 554 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00184548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00184548 about?
NCT00184548 is a clinical study titled "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding". This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity. Please note that this trial and trial F7TRAUMA-1648 (NCT00...
What is the current status of trial NCT00184548?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 554 participants. The study started on 2005-10. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00184548?
The interventions under investigation include: placebo (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00184548?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.